Artivion (AORT) Cash from Investing Activities (2010 - 2026)
Artivion (AORT) posted Cash from Investing Activities of -$10.5 million for Q1 2026, up 65.57% on a QoQ basis from -$30.5 million in Q4 2025, and down 188.7% year-over-year from $11.8 million in Q1 2025.
Artivion (AORT) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Artivion's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$10.5 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 188.7% year-over-year to -$10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$48.9 million (down 73.33% YoY) and the FY2025 annual result came in at -$42.0 million, down 49.15% from the prior year.
- Cash from Investing Activities was -$10.5 million for Q1 2026 at Artivion, up from -$30.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7.1 million in Q2 2023 and bottomed at -$30.5 million in Q4 2025.
- A 5-year average of -$5.4 million and a median of -$3.1 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 409.62% — and 2024, when it plunged 414.46%.
- Artivion's Cash from Investing Activities stood at -$2.7 million in 2022, then slipped by 0.04% to -$2.7 million in 2023, then tumbled by 328.06% to -$11.4 million in 2024, then slumped by 167.02% to -$30.5 million in 2025, then surged by 65.57% to -$10.5 million in 2026.
- Business Quant data shows AORT's Cash from Investing Activities at -$10.5 million in Q1 2026, -$30.5 million in Q4 2025, and -$4.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -298.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -475.32 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.50 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Artivion | 1.25 Bn | 1.19 Bn | 75.45 Mn | -10.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.50 Mn |
| Mar 31, 2026 | -10.50 Mn |
| Dec 31, 2025 | -30.51 Mn |
| Dec 31, 2025 | -30.51 Mn |
| Sep 30, 2025 | -4.61 Mn |
| Sep 30, 2025 | -4.61 Mn |
| Jun 30, 2025 | -3.29 Mn |
| Jun 30, 2025 | -3.29 Mn |
| Mar 31, 2025 | -3.64 Mn |
| Mar 31, 2025 | -3.64 Mn |
| Dec 31, 2024 | -11.43 Mn |
| Dec 31, 2024 | -11.43 Mn |
| Sep 30, 2024 | -10.64 Mn |
| Sep 30, 2024 | -10.64 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -3.61 Mn |
| Mar 31, 2024 | -3.61 Mn |
| Dec 31, 2023 | -2.67 Mn |
| Dec 31, 2023 | -2.67 Mn |